SELECTION OF PATIENTS FOR RANDOMIZED CONTROLLED TRIALS - IMPLICATIONS OF WIDE OR NARROW ELIGIBILITY CRITERIA

被引：78

作者：

YUSUF, S

HELD, P

TEO, KK

TORETSKY, ER

机构：

[1] Clinical Trials Branch, Division of Epidemiology and Clinical Application, National Heart, Lung, and Blood Institute, Bethesda, Maryland

[2] Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina

来源：

STATISTICS IN MEDICINE | 1990年 / 9卷 / 1-2期

关键词：

D O I：

10.1002/sim.4780090114

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This paper discusses the various philosophies that influence the selection of patients for entry into randomized controlled trials. Although a number of different and often competing issues have to be considered depending upon the trial, keeping entry criteria simple, wide and at times even flexible is usually preferable. Such a strategy can be a positive virtue by helping to attain the large numbers of patients that are usually needed to reliably detect the sorts of moderate benefits that are plausible, at a reasonable cost and by providing answers that are relevant to many different categories of patients with a particular condition. Copyright © 1990 John Wiley & Sons, Ltd.

引用

页码：73 / 86

页数：14

共 17 条

[1] Yusuf S., Wittes J., Friedman L., Overview of results of randomized clinical trials in heart disease: 1. Treatments following myocardial infarction, Journal of the American Medical Association, 260, pp. 2088-2093, (1988)
[2] Randomized trial of IV streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction, Lancet, 2, pp. 349-360, (1988)
[3] Secondary prevention of vascular disease by prolonged antiplatelet treatment, British Medical Journal, 296, pp. 320-331, (1988)
[4] Theroux P., Ourlette H., McCans J., Latour J.G., Joly P., Levy G., Pelletier E., Juneau M., Stasiak J., deGuise P., Pelletier G.B., Rinzler D., Waters D.D., Aspirin and heparin or both to treat acute unstable angina, New England Journal of Medicine, 319, pp. 1105-1111, (1988)
[5] Cairns J.A., Gent M., Singer J., Finnie K.J., Froggatt G.M., Holder D.A., Jablonsky G., Kostuk W.J., Melendez L.J., Myers M.G., Sackett D.L., Sealy B.J., Tanser P.H., Aspirin on sulfinpyrazone or both in unstable angina, New England Journal of Medicine, 313, pp. 1369-1375, (1985)
[6] Lewis D.H., Davis J.W., Archibald D.G., Et al., Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina, New England Journal of Medicine, 309, pp. 396-403, (1983)
[7] Marder V., Sherry S., Thrombolytic therapy: current status, New England Journal of Medicine, 318, pp. 1512-1520, (1988)
[8] Yusuf S., Sleight P., Held P., McMahon S., (1989)
[9] Chadda K., Goldstein S., Byington R., Curb J.D., Effect of propranolol after acute myocardial infarction in patients with congestive heart failure, Circulation, 73, pp. 503-510, (1986)
[10] Risk stratification and survival after myocardial infarction, New England Journal of Medicine, 309, pp. 331-339, (1983)

← 1 2 →